Insulin is a peptide hormone produced by pancreatic β-cells within the islets of Langerhans and serves as the body’s principal anabolic hormone, uniquely capable of lowering plasma glucose concentrations.
Normal fasting insulin levels generally range from 5 to 15 mu/mL though many experts consider 2–6 U/mL to be optimal for long-term metabolic health.
The regulation of insulin secretion is primarily governed by glucose-stimulated insulin secretion (GSIS), a tightly orchestrated process in which glucose enters β-cells via the GLUT-2 transporter and is phosphorylated by glucokinase, the rate-limiting enzyme in β-cell glucose metabolism.
Subsequent glycolysis and mitochondrial oxidative metabolism increase the intracellular ATP:ADP ratio, which triggers closure of ATP-sensitive potassium (K_ATP) channels composed of SUR1 and Kir6.2 subunits.
This closure depolarizes the β-cell membrane, opening voltage-gated calcium channels and allowing calcium influx, which is the immediate trigger for exocytosis of insulin-containing secretory granules.
Chronically elevated insulin often precedes high blood sugar and diabetes by years, with levels over 10 μ/m potentially indicating insulin resistance.
Insulin levels refer to how much insulin hormone is present in the blood at a given time and are usually interpreted together with glucose to assess insulin production, resistance, or excess.
While standard labs may consider up to 25 μmL normal, many experts suggest keeping fasting levels under 10 mU/mL, or ideally under 6 mU/mL, to reduce metabolic risk.
If the insulin level is high but glucose is normal, it may indicate insulin resistance, where cells don’t respond efficiently to insulin, causing the pancreas to produce more.
High insulin is often driven by obesity, especially visceral fat, lack of physical activity, and diets high in refined carbohydrates.
Causes of Low Insulin: Usually indicates the pancreas cannot produce enough, commonly seen in Type 1 diabetes or advanced pancreas issues.
High intake of processed food and sugar increases fasting insulin.
Exercise: Physical activity improves insulin sensitivity, allowing lower insulin levels.
PCOS, metabolic syndrome, and fatty liver disease are strongly associated with high insulin levels.
Insulin is a pancreatic hormone that lets glucose move from the bloodstream into muscle, fat, and liver cells for energy or storage.
When blood glucose rises after a meal, insulin secretion increases; when glucose normalizes, insulin secretion falls.
There is no single universal “normal” insulin level because secretion varies by person, time of day, and meal context.
Many labs report fasting free insulin as “normal” when less than about 17 μU/mL, but reference ranges differ and must be interpreted with clinical context.
High insulin with normal or slightly high glucose often indicates insulin resistance or early prediabetes.
Low insulin with high glucose suggests impaired beta‑cell function, as in type 1 diabetes or advanced type 2, or pancreatic disease.
Inappropriately high insulin in the setting of hypoglycemia raises concern for excess insulin; exogenous insulin use, insulinoma.
Fasting insulin may be used with fasting glucose to estimate insulin resistance or metabolic risk, though it is not a standard screening test in all guidelines.
Dynamic tests such as oral glucose tolerance with insulin levels can show exaggerated insulin spikes typical of insulin resistance.
Insulin levels are most useful when interpreted along with glucose, A1c, lipids, body habitus, and clinical picture rather than as an isolated number.
Mitochondrial pathways, generate additional coupling factors that sustain insulin secretion beyond the initial calcium signal.
Beyond glucose, amino acids, particularly arginine and leucine, and fatty acids potentiate insulin release through direct depolarization or activation of G-protein-coupled free fatty acid receptors.
Incretin hormones, notably glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), released from the gut in response to nutrient ingestion, amplify GSIS via cAMP-mediated pathways.
Neurohormonal regulation is also significant: parasympathetic (cholinergic) stimulation enhances insulin release, while sympathetic (adrenergic) stimulation generally inhibits it, and the cephalic phase of insulin secretion primes β-cells for subsequent nutrient-induced secretion.
Paracrine signals within the islet, including somatostatin from δ-cells and glucagon from α-cells, further modulate β-cell function.
Once secreted, insulin binds to the insulin receptor, a transmembrane tyrosine kinase, on target tissues including muscle, adipose tissue, and liver.
This initiates a phosphorylation cascade through the phosphoinositide 3-kinase (PI3K)/Akt pathway, leading to translocation of GLUT-4 glucose transporters to the cell membrane in muscle and adipose tissue, thereby facilitating glucose uptake.
In the liver, insulin suppresses gluconeogenesis and promotes glycogen synthesis, while in adipose tissue it stimulates lipogenesis and inhibits lipolysis.
Insulin is most commonly measured in clinical practice using immunoassays, including enzyme-linked immunosorbent assays (ELISA), chemiluminescent immunoassays (CLIA), and, less frequently, radioimmunoassays (RIA).
These assay’s specificity varies depending on antibody cross-reactivity with proinsulin, split products, and insulin analogs.
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is increasingly used for its superior specificity, with detection limits as low as 1.8 μIU/mL, and the ability to distinguish endogenous insulin from exogenous analogs.
Insulin concentrations are reported in either international units per milliliter (μIU/mL or mU/L) or molar units (pmol/L), with the conversion factor approximately 1 μIU/mL = 6 pmol/L.
Serum insulin is stable for up to 7 days at 2–8°C, one month at −20°C, and six months at −70°C; hemolysis can degrade nearly all insulin in a sample, leading to falsely low results.
Normal fasting insulin reference ranges in healthy adults typically fall between 2–12 μU/mL, though the upper limit may extend to 15–16 μU/mL depending on the assay and population studied.
Using electrochemiluminescence immunoassay, reported a 95% reference interval of 2.11–12.49 μU/mL in healthy Iranian adults.
The IMx-Abbott enzyme immunoassay, found median fasting insulin values of 5.1–5.6 μU/mL, with the 95th percentile at 11.2–12.6 μU/mL.
In elderly populations, a Swedish cohort of 75-year-olds showed a 2.5th–97.5th percentile of 1.66–15.05 mIU/L for those with BMI ≤30.
Postprandial insulin reference ranges are even more assay- and population-dependent, with significant gender differences observed at 30 and 120 minutes post-glucose load.
Even assays claiming traceability to the WHO 66/304 standard can differ by as much as ±300 pmol/L relative to LC-MS/MS reference methods.
Metformin’s antihyperglycemic effect directly influences insulin levels.
Hyperinsulinemia refers to elevated circulating insulin levels and is most commonly a compensatory response to insulin resistance, as seen in obesity, metabolic syndrome, and early type 2 diabetes.
Chronic hyperinsulinemia is both an adaptive response and a pathogenic driver, contributing to further metabolic dysfunction through downregulation of insulin signaling, stimulation of the adrenergic nervous system, and promotion of anti-natriuresis.
The San Antonio Heart Study demonstrated prospectively that elevated fasting insulin precedes the development of hypertension, dyslipidemia, and type 2 diabetes.
Primary insulin hypersecretion, independent of insulin resistance, has been identified in nondiabetic adults and adolescents and is associated with a worse metabolic phenotype and increased risk of progression to impaired glucose tolerance.
Reduced hepatic insulin clearance is another mechanism contributing to hyperinsulinemia, particularly in apparently healthy non-obese young adults.
Hyperinsulinemia is a central feature of metabolic syndrome, which clusters central obesity, hypertension, atherogenic dyslipidemia, and impaired glucose regulation.
It is also associated with polycystic ovary syndrome (PCOS), nonalcoholic fatty liver disease (NAFLD), obstructive sleep apnea, chronic kidney disease, and certain cancers.
Mendelian randomization studies support a causal link between elevated insulin levels and cardiovascular risk.
Insulinoma, a rare pancreatic neuroendocrine tumor, causes persistent hyperinsulinemia and recurrent hypoglycemia due to autonomous insulin secretion, and is diagnosed by demonstrating inappropriately elevated insulin and C-peptide during hypoglycemic episodes.
Hypoinsulinemia is characteristic of type 1 diabetes, resulting from autoimmune β-cell destruction, and of advanced type 2 diabetes, where progressive β-cell dysfunction leads to declining insulin secretion.
In type 1 diabetes, absolute insulin deficiency causes hyperglycemia, polyuria, polydipsia, weight loss, and risk of diabetic ketoacidosis.
In type 2 diabetes, the transition from hyperinsulinemia to hypoinsulinemia reflects the natural history of β-cell failure, with fasting glucose levels above 140 mg/dL generally associated with hypoinsulinemia on oral glucose tolerance testing.
The ADA recommends C-peptide measurement in ambiguous cases to distinguish between type 1 and type 2 diabetes, as C-peptide reflects endogenous insulin production and is not affected by exogenous insulin therapy.
The ADA, in its 2023 guidelines, restricts the clinical use of insulin measurement to specific diagnostic scenarios.
The primary indication is the evaluation of unexplained hypoglycemia, particularly when insulinoma is suspected; an end-of-fast insulin ≥3 μIU/mL with concurrent hypoglycemia has 98% sensitivity for insulinoma, and an end-of-fast proinsulin ≥22 pmol/L best discriminates insulinoma from controls (100% sensitivity, 100% specificity).
Measurement of insulin, C-peptide, and proinsulin is also essential to distinguish endogenous hyperinsulinemia from surreptitious exogenous insulin administration.
Routine measurement of insulin is explicitly not recommended for diabetes diagnosis, screening, management, cardiovascular risk stratification, or assessment of insulin resistance in PCOS or metabolic syndrome.
Physical signs (BMI, acanthosis nigricans) are sufficient for clinical assessment of insulin resistance.
Consensus report on management of hyperglycemia in type 2 diabetes similarly does not recommend insulin measurement for guiding therapy selection.
Prediabetes, diagnosis relies on fasting plasma glucose, HbA1c, or 2-hour post-glucose values, not insulin levels.
Significant sources of error in insulin assays include interference from insulin antibodies, both insulin autoantibodies in insulin autoimmune syndrome and anti-insulin antibodies from exogenous therapy. variable cross-reactivity with insulin analogs, and specimen handling issues.
Some immunoassays fail to detect commonly prescribed insulin analogs, with cross-reactivity ranging from 0% to over 140% for a single analog.
Lifestyle factors and medications profoundly affect insulin levels and their interpretation.
Calorie restriction and sustained weight loss of ≥5% significantly reduce fasting and postprandial insulin concentrations, with weight loss ≥15% capable of inducing type 2 diabetes remission (HbA1c).
Exercise increases insulin sensitivity in a dose-dependent manner, with post-exercise insulin sensitivity remaining elevated for up to 48 hours.
It is recommend at least 150 minutes per week of moderate-intensity aerobic activity for individuals with type 2 diabetes.
Metformin, the most widely prescribed oral antidiabetic, reduces fasting and postprandial insulin concentrations by decreasing hepatic glucose output and enhancing peripheral glucose uptake.
Metformin treatment in patients with non-insulin-dependent diabetes mellitus significantly reduced fasting plasma glucose, hepatic glucose output, and plasma insulin concentrations, with a strong correlation between hepatic glucose output and fasting plasma glucose both before and after treatment.
Glucocorticoids are a common cause of medication-induced hyperglycemia, with an incidence of glucocorticoid-induced diabetes of 18–32% in those treated with supraphysiologic doses of ≥5 mg prednisolone or equivalent.
The ADA recommends screening via postprandial or random glucose rather than fasting glucose, as glucocorticoid-induced hyperglycemia is predominantly postprandial.
Metformin can be considered to prevent glucocorticoid-induced hyperglycemia in high-risk individuals, as demonstrated in randomized trials showing improved insulin resistance, β-cell function, and glucose concentrations.
Other medications associated with increased insulin resistance and hyperinsulinemia include statins, thiazide diuretics, second-generation antipsychotics, and certain HIV medications.
Insulin reference ranges and clinical interpretation differ significantly across the lifespan.
In children, fasting insulin increases from approximately 13–17 pmol/L at age 3 to 43–54 pmol/L by age 11, with girls exhibiting higher values at all ages, reflecting physiological pubertal insulin resistance.
In the elderly, fasting insulin reference intervals are higher (1.74–18.27 mIU/L at age 75), reflecting age-related insulin resistance and comorbidities.
During pregnancy, insulin secretion intrinsically increases in early pregnancy, and insulin resistance rises markedly after 16 weeks, often resulting in a doubling of daily insulin requirements by late pregnancy.
The ADA recommends frequent insulin titration guided by glucose monitoring, with fasting glucose goals of 70–95 mg/dL and 1-hour postprandial values
A rapid and significant reduction in insulin requirements in late pregnancy may signal placental insufficiency.
Technological advances in point-of-care and continuous insulin monitoring, including wearable electrochemical biosensors, hold promise for real-time insulin measurement and integration with closed-loop insulin delivery systems.
Routine measurement is not recommended for diabetes diagnosis, management, or cardiovascular risk stratification.